2013 Fiscal Year Final Research Report
Development of novel therapies targeting esophageal cancer using Midkine inhibitors
| Project/Area Number |
23591950
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Kawasaki Medical School |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YAMATSUJI Tomoki 川崎医科大学, 医学部, 准教授 (40379730)
FUKAZAWA Takuya 川崎医科大学, 医学部, 講師 (20379845)
TAKAOKA Munenori 川崎医科大学, 医学部, 講師 (50548568)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
NAKAJIMA Motowo 東京大学, 分子細胞生物学研究所, 客員教授 (90240738)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Keywords | 食道癌 / 肺癌 / Midkine |
|---|
| Research Abstract |
Midkine is a heparin-binding growth factor that is highly expressed in many malignant tumors. Therefore,the inhibition of Midkine is considered a potential strategy forcancer therapy. In the present study, we demonstrate a novel small molecule compound:MDK#3 that targets Midkine. MDK#3 suppressed the cell growth of Midkine-positive esophageal cancer cells and pulmonary adenocarcinoma cells. However, the inhibitor did not reduce the cell viability of normal human lung fibroblast cells.MDK#3 increased caspase-3 activity and apoptosis in MDK positive pulmonary adenocarcinoma cell. These results imply that inhibition of Midkine with MDK#3 provides a potential therapeutic approach for the treatment of esophageal cancer and lung cancer that are driven by Midkine.
|
-
[Journal Article]2013
Author(s)
Hao H, Maeda Y, Fukazawa T, Yamatsuji T, Takaoka M, Bao XH, Matsuoka J, Okui T, Shimo T, Takigawa N, Tomono Y, Nakajima M, Fink-Baldauf IM, Nelson S, Seibel W, Papoian R, Whitsett JA, Naomoto Y.
-
Journal Title
PLoS One
Volume: 8(8)
Pages: e71093
Peer Reviewed
-
-
-
-
